Today, advancements in medicine have rendered HIV a manageable condition that allows most individuals to enjoy a typical ...

An HIV vaccine candidate developed at the Duke Human Vaccine Institute (DHVI) triggered low levels of an elusive type of broadly neutralizing HIV antibodies among a small group of people enrolled in a ...

A dual-action HIV antibody–drug conjugate forces Env to open, then blocks it, boosting virus neutralization up to tenfold in the lab.

Add Yahoo as a preferred source to see more of our stories on Google. Scientists have discovered a powerful antibody, 04_A06, that neutralizes almost every known strain of HIV-1. (CREDIT: Shutterstock ...

A new study published in The Lancet Microbe reports the first twice-yearly injectable HIV treatment regimen—combining lenacapavir, teropavimab, and zinlirvimab—has achieved high rates of viral ...

An international research team has identified a novel HIV antibody that targets the virus at a particularly vulnerable site and overcomes previous limitations of known antibodies. This study, led by ...

The development of antiretroviral therapy, a combination of drugs that slows the replication of HIV in the body, has transformed the treatment of this infection. What was once a certain death sentence ...

In the continuing search for the Achilles heel of HIV, researchers may finally be enjoying some success. This week, government researchers at the Vaccine Research Center of the National Institute of ...

Lipids are the fatty molecules that make up cellular membranes, creating a protective barrier that regulates what enters and exits the cell. Until recently, scientists believed antibodies couldn't ...

What are the three types of HIV tests available to patients, how do they differ, and how can patients determine the best option for them?

Three different HIV antibodies each independently protected monkeys from acquiring simian-HIV (SHIV) in a placebo-controlled proof-of-concept study intended to inform development of a preventive HIV ...

Monotherapy with UB-421 may suppress human immunodeficiency virus (HIV) for up to 4 months in infected patients undergoing a short-term antiretroviral therapy (ART) pause, according to a study ...